Imvax

Please note: The information displayed on this page might be outdated.
Imvax: Imvax™ is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies. Imvax’s portfolio includes several programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax’s most advanced program is IGV-001 for the treatment of glioblastoma. Imvax’s immunotherapy platform is a multi-step process designed to deliver personalized, whole tumor-derived immunotherapies.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Oncology
Listing
Private
Website:
Address:
601 Walnut St
Suite 440W
Philadelphia, PA 19106
United States

Company Participants at Fall Private Company Showcase 2022

  • Josh Muntner, Chief Financial Office